Kornimate/medical-research-clean huggingface dataset:
treatment of postoperative pain after total knee arthroplasy using intravenous lidocaine infusion

Conditions: Total Knee Arthroplasty

Summary: total knee replacement is often associated with severe postoperative pain, especially in the first 24 hours. patient controlled analgesia (pca) and continuous femoral block with pca are commonly used to treat postoperative pain after total knee arthroplasty. however, pcas use opioids. opioids are excellent painkillers but their use is hampered by side effects such as nausea, vomiting, bowel dysfunction, urinary retention, pruritus, sedation and respiratory depression. we propose to test the hypothesis that adding a low dose lidocaine infusion to pcas will lower the amount of opioids that these patients receive, thereby improving patient safety while still providing adequate analgesia. in addition, continuous femoral block has been shown to provide superior postoperative pain control when compared to morphine pca. therefore, postoperative pain levels of study subjects will be compared to those subjects who receive a combination of a continuous femoral block catheter with a pca.


Eligibility criteria:
inclusion criteria: 1. undergoing a total knee arthroplasty 2. be american society of anesthesiologist physical status 1,2, or 3 3. be willing and capable of providing informed consent 4. be english speaking exclusion criteria: 1. age greater than 80 years old or younger than 18 years old 2. congestive hear failure 3. hepatic insufficiency 4. neurological disorders 5. psychiatric disorders 6. steroid treatment 7. history of atrial fibrillation 8. chronic pain disorder with opioid treatment

Keywords: total knee arthroplasty intravenous lidocaine infusion femoral block catheter
health evaluation of abilify long-term therapy

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment. the health profiles during the switching period, after 12 weeks short-term use, and after 52 weeks long-term use of aripiprazole will be recorded and evaluated.

further study details as provided by taiwan otsuka pharmaceutical co., ltd.

Eligibility criteria:
inclusion criteria: 1. male or female patients between the ages of 18 to 65. 2. having a dsm-iv diagnosis of schizophrenia or schizoaffective disorder. 3. who are currently taking antipsychotic drugs and clinically intolerable or inadequately controlled that is based upon the clinical judgment of the investigator. exclusion criteria: 1. pregnant or breast feeding women or planning a pregnancy. 2. patient received electroconvulsive therapy within 4 weeks before the screening visit. 3. a known allergy reaction to any antipsychotic medication (including but not limited to haloperidol, chlorpromazine, thioridazine, pimozide, risperidone, quetiapine, ziprasidone). 4. patient has clinically relevant organic, neurological, or cardiovascular diseases. 5. patient has a history of drug or alcohol abuse within the last 12 weeks. 6. acute psychosis, acute suicidal ideation, or any acute psychiatric condition that might require emergent intervention. 7. any clinical condition or significant concurrent disease judged by the investigator to complicate the evaluation of the study treatment. 8. having participated other investigational drug study and taken the investigation drug within one month prior to study entry. 9. depot neuroleptics should be discontinued at least 2 months prior to enrollment.
olanzapine in patients with borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: the goals of this study are to determine: the safety of olanzapine and any side effects that might be associated with it, how olanzapine compares to placebo, whether olanzapine can help patients with symptoms of borderline personality disorder (bpd), and how much olanzapine should be given to patients.


Eligibility criteria:
inclusion criteria: * patients must be of outpatient status at visit 1 and through visit 2. * patients must be 15 to 65 years of age at visit 1. * patients must meet all of the dsm-iv-tr general diagnostic criteria for a personality disorder and patients must meet dsm-iv-tr diagnostic criteria for bpd. * the symptom severity as assessed by the total score of the zan-bpd, confirmed by a psychiatrist with training in the evaluation and assessment of bpd, must be greater than or equal to 9 at visit 2. * female patients of childbearing potential must test negative for pregnancy and must be using a medically accepted means of contraception throughout the course of the study. exclusion criteria: * patients must not be investigators, study site personnel directly affiliated with the study, or immediate family of investigator site personnel directly affiliated with the study. immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * persons employed by lilly (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). immediate family of lilly employees may participate in lilly-sponsored clinical trials, but are not permitted to participate at a lilly facility. immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. * patients must not have previously participated (have been randomized) or withdrawn from this study or any other lilly sponsored study investigating olanzapine. * patients must not have had previous treatment with olanzapine unless, in the opinion of the investigator, the patients' previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of olanzapine was confounded by concomitant medication. * female patients must not be pregnant or nursing.
retreatment study of galiximab + rituximab in follicular non-hodgkin's lymphoma (nhl)

Conditions: Lymphoma, Non-Hodgkin's

Summary: this is a phase iii, multicenter, global, open-label, single-arm, retreatment study of an investigational drug called galiximab in combination with an approved drug called rituximab in subjects with relapsed or refractory, follicular nhl who demonstrated a response on study 114-nh-301 with a time-to-progression \>=6 months.


Eligibility criteria:
key inclusion criteria: * demonstrated a response (cr, cru, or pr) on study 114-nh-301 (galiximab in combination with rituximab compared with rituximab in combination with placebo) and then relapsed or progressed with a ttp \>=6 months. relapsed disease is defined as documented disease progression using the international workshop response criteria (iwrc). * bidimensionally measurable disease with at least 1 lesion \>=2.0 cm in a single dimension. * acceptable hematologic, hepatic, and renal function. key exclusion criteria: * any lymphoma therapy between final visit on study 114-nh-301 and study day 1 of this retreatment study. * chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to study day 1. * transfusion-dependent subjects. * presence of central nervous system (cns) lymphoma. * histologic transformation. * presence of pleural or peritoneal effusion with positive cytology for lymphoma. * another primary malignancy requiring active treatment. * serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the investigator and/or the sponsor. * new york heart association class iii or iv cardiac disease or myocardial infarction within 6 months prior to study day 1.

Keywords: galiximab antibody refractory follicular relapsed nhl rituximab retreatment
immediate effects of kinesio taping and manual release in young adults with pes planus

Conditions: Pes Planus

Summary: pes planus is a postural deformity seen with decreased medial longitudinal arch (mla) height and this causes intense stress on the plantar fascia. pes planus may affect individuals' activities of daily living, their productivity in occupational environments, and the risk of injury and performance in sports; it has also been reported that it may cause different musculoskeletal diseases such as plantar fasciitis, medial tibial stress syndrome, patellofemoral disorders and back pain in the future. many clinical methods are used as a treatment for pes planus and most treatments involve supporting an overstretched plantar fascia and weakened mla. the aim of the study is to investigate the immediate effects of kinesio taping and manual release on lower extremity performance in young adults with pes planus.

this study is a randomized controlled trial, will be carried out on volunteer individuals with pes planus aged between 18-25, studying at ankara yıldırım beyazıt university. evaluation of parameters and inclusion criteria, kinesio taping and manual release applications will be made by the physiotherapist. individuals who meet the inclusion criteria, who volunteered to participate in the study and signed the consent sheet will be randomly divided into two groups, group 1 \[manual release (mr)\] and group 2 \[kinesio taping (kt)\]. a simple randomization method will be used with opaque sealed envelopes containing "1" or "2". group allocation will be performed by an independent therapist, not involved in the study. all individuals will be evaluated with timed up-and-go test, heel rise test, 10-meter walking test, and functional reach test before and after the intervention. manual release will be applied to group 1 after the evaluation and the evaluations will be repeated immediately the end of the application. kinesio taping will be applied to group 2 after the evaluation and the evaluations will be repeated 45 minutes after the end of the application.

Eligibility criteria:
inclusion criteria: * individuals who volunteer to participate in the study * individuals with bilateral pes planus * individuals who have not had any ankle injury in the last 6 months exclusion criteria: * individuals with severe visual and hearing impairment * individuals with congenital shortness or deformity in their lower extremities * individuals who have had any lower extremity surgery * individuals with hallux valgus, hallux rigidus, or calcaneal epine * individuals with any musculoskeletal problem other than pes planus and systemic, neurological problems * individuals with chronic ankle instability * individuals who have had problems walking for the last 6 months * individuals who have received treatment for pes planus in the last 6 months and use insoles

Keywords: pes planus kinesio taping manual release plantar fascia
rct comparing evla versus polidocanol foam in the treatment of ssv insufficiency

Conditions: Varicose Veins of Lower Limb

Summary: fovelass is a multicentre-rct (11 centres) comparing ultrasound-guided-foam sclerotherapy (ugfs) and endovenous laser ablation (evla) for treating ssv insufficiency, conducted by the french society of phlebology.

saphenous vein insufficiency is a common finding in varicose veins cases. international guidelines currently recommend endovenous thermal ablation using laser (evla) or radiofrequency as first line treatment for truncal great saphenous vein (gsv) incompetence in preference to ultrasound guided foam sclerotherapy (ugfs) (1,2). this gsv-based recommendation has tended to be used for treating small saphenous vein (ssv) incompetence. to date, no rcts have directly compared ugfs and evla for ssv treatment. the french society of phlebology (sfp) decided to compare these two most utilised endovenous treatments in france in a controlled study called the foam versus laser in the ssv (fovelass) study, involving 13 investigators in 11 vascular medical centres.

Eligibility criteria:
inclusion criteria: * symptomatic varicose veins (ceap c2s-c6) * underlying isolated ssv incompetence (ssv reflux time\>0.5sec on duplex ultrasound (dus)) * reflux involving at least 15 cm of proximal ssv * minimal ssv diameter of 4 mm at mid-calf (luminal diameter in standing position) exclusion criteria: * ssv treatment in the preceding 3 months * post-thrombotic disease * deep or superficial vein thrombosis of less than 3 months duration * coexistent ipsilateral gsv insufficiency * morbid obesity (bmi\>40) * presence of significant arterial disease (abpi\<0.5)

Keywords: small saphenous veins varicose veins ultrasound guided foam sclerotherapy endovenous laser ablation
tour de borobudur troponin study on predictors and synergistic role of mda and hs-crp levels

Conditions: Heart Arrest; Sport Injury; Inflammatory Response; Oxidative Stress

Summary: prospective observational study to determine predictors that related to cardiac troponin i (ctni) release, malondialdehyde (mda) and high sensitivity c reactive protein (hs-crp) after tour de borobudur (tdb) 2017

eligible criteria: 1. minimum sample size of 80 men, non-athlete, participants of tdb 2. classified into two groups: 160kms cycling and 100kms cycling participation 3. 25-55 years old 4. voluntary participate in the research 5. eligible in pre participatory physical examination and ecg test by the doctor 6. have no history of the previous acute coronary syndrome (acs) measurements: interview for determining predictors of sports participation history, medical history, family medical history and rate of perceived exertion measurement and examination to determine: anthropometry parameters, clinical conditions (systolic bp, diastolic bp, hemoglobin levels, t-cholesterol and hdl-c levels, the intensity in cycling activities (mileage, velocity, duration, and time for resting), hemodynamic responses (average and maximum heart rate, karvonen index), and hydration status other outcome measurements; pre and post-tdb 2017 measurements of ctni, mda, and hs-crp

Eligibility criteria:
inclusion criteria: * minimum sample size of 80 men, non athlete, participants of tdb * classified into two groups: 160kms cycling and 100kms cycling participation * 25-55 years old * voluntary participate in the research * eligible in pre participatory physical examination and ecg test by doctor have no history of previous acute coronary syndrome (acs) exclusion criteria: * stop cycling before finish line due to mechanical or bicycle related errors * (subjects who stop cycling due to any physical symptoms and health related problem included in analysis)

Keywords: troponin-i hs-crp malondialdehyde predictors
noac plasma concentration and blood coagulation in healthy volunteers

Conditions: Blood Coagulation Disorder

Summary: relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis


Eligibility criteria:
inclusion criteria: healthy exclusion criteria: intolerance of the study drug history of bleeding disorder or similar
effects of internet-based treatment of pathological gambling

Conditions: Pathological Gambling

Summary: a trial testing the outcome of an internet-based treatment of pathological gambling with the hypothesis that there will be improvements both immediately and up to 36 months. it is also hypnotized that treatment response can be predicted from background variables.


Eligibility criteria:
inclusion criteria: * pathological gambling according to dsm and having gambled at least once the past month * being atleast 18 years old * living in sweden exclusion criteria:

Keywords: pathological gambling according to dsm and having gambled at least once the past month. being atleast 18 years old
primary care-based physical activity for diabetic latinas

Conditions: Diabetes; Sedentary Lifestyle

Summary: the goal of this proposal is to test the efficacy of a primary care-delivered, print-based physical activity intervention for latinas with type ii diabetes. the investigators will test the efficacy of this intervention by randomizing 80 latinas with type ii diabetes recruited through ucsd health system primary care to either the adapted web-based physical activity intervention or standard of care, and assessing physical activity gains at six and 12 months. the ultimate goal is to develop a print-based physical activity intervention for diabetic latinas that could be widely disseminated through primary care.

studies show that adoption of regular physical activity (pa) can greatly enhance diabetes management and prevention. individuals who adopt a pa routine show significant improvements in clinical markers of diabetes, including hba1c, glucose tolerance, insulin sensitivity, weight and waist circumference, and significant reductions in medication use, and also show reductions in cardiovascular risk factors and other related co-morbidities. incorporation of cost-effective pa interventions into primary care for diabetes treatment could therefore enhance overall health and quality of life and significantly reduce healthcare costs. the primary aim of this study is to conduct a small randomized trial (n=80) to test the efficacy of an individually tailored culturally adapted print-based physical activity intervention integrated into primary care to increase weekly moderate-to-vigorous physical activity in latinas with type ii diabetes, compared to those receiving standard of care.

Eligibility criteria:
inclusion criteria: * have received a physician's diagnosis of type ii diabetes and are currently being seen by a primary care physician * currently inactive, defined as participating in at least moderate intensity physical activity for less than 60 minutes per week exclusion criteria: * medical condition that may make exercise unsafe, including congestive heart failure, severe musculoskeletal problems or pulmonary conditions, or other conditions determined by the referring physician to preclude unsupervised exercise * unable to receive mailed materials (do not have a mailing address) * unable to engage in physical activity for at least 30 minutes * have a current or planned pregnancy * planning to move from the area within the next year
the effect of smoking status of the patient on the success of etanercept therapy in psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: the main purpose of this study is to assess the effect of smoking status on the success of etanercept therapy in patients with moderate-to-severe psoriasis.

study hypothesis was based on the following rationale: * psoriasis vulgaris is a chronic inflammatory skin disease with several extracutaneous manifestations and significant comorbidities (among others cardiovascular disease, metabolic syndrome, obesity and depression). * an increased prevalence of smoking among psoriasis patients, as compared with healthy subjects, has been observed in several studies * more recent studies suggest that cigarette smoking may trigger the development of psoriasis through oxidative, inflammatory and genetic mechanisms.furthermore, smoking is associated with the clinical severity of psoriasis * smoking also contributes to higher morbidity and mortality from smoking related disorders in these patients there is now some evidence that patients with psoriasis who smoke tend to be less responsive to treatment

Eligibility criteria:
inclusion criteria: * adult patients aged ≥18 years at the time of screening * clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by the subjects medical history, and confirmation of the diagnosis through physical examination by the investigator * patients who are scheduled by their dermatologist to initiate treatment with etanercept prescribed independently by the investigator as per local clinical practice guideline * stable plaque psoriasis for at least 2 months prior to baseline * diagnosis of severe psoriasis defined as pasi \> 10 * eligible for etanercept treatment according to summary of product characteristics (smpc) * smokers with smoking \>10 cigarettes daily for smokers group (group 1) or non-smokers for non-smoking group (group 2) * evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the study exclusion criteria: * previous or current treatment with antipsoriatic biologic drugs, such as etanercept, infliximab, adalimumab, ustekinumab, alefacept, efalizumab. * exclusion criteria according to the enbrel® smpc, with particular attention to: hypersensitivity to the active substance (etanercept) or to any of the excipients; sepsis or risk of sepsis, active infections, including chronic or localised infections. * positive pregnancy test, breast feeding or considering becoming pregnant during the study * clinically significant drug or alcohol abuse
cocooned moms study

Conditions: Stress; Depression; Pregnancy; Blood Pressure

Summary: the cocooned moms study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant black women by providing them with free access to the inovcares mobile app. inovcares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. it also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (cbt), interpersonal therapy, and compassion-focused therapy (cft), along with peer-to-peer support and gamification. the study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (bp) among black pregnant women.


Eligibility criteria:
inclusion criteria: - black women ages 18 + with confirmed pregnancy of at least eight or up to 28 weeks, with no known fetal or genetic abnormalities (with the exception of abnormal amniotic fluid volume; women who have the developmental or legal capacity to consent; able to speak english exclusion criteria: * exclusion criteria 1. psychosis diagnosis 2. does not speak or understand english 3. participants who are not pregnant 4. non-black 5. significant vision impairment.